Stockreport

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biops [Read more]